Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2331734 | 0.81 | ESR1 (0.56) | ESR1KDM4EALDH1A1ESR2 | |
| SCHEMBL2332018 | 0.80 | PTPN1 (0.47) | ESR1ESR2 | |
| SCHEMBL17516321 | 0.76 | ESR1 (0.39) | ESR1KDM4EALDH1A1ESR2 | |
| SCHEMBL2361513 | 0.76 | ESR1 (0.39) | ESR1KDM4EALDH1A1ESR2 | |
| SCHEMBL2332295 | 0.74 | ALDH1A1 (0.76) | ESR1KDM4EALDH1A1ESR2 | |
| SCHEMBL2332170 | 0.73 | CA1 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL1616936 | 0.72 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL5038858 | 0.72 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL2327901 | 0.69 | ESR1 (0.63) | ESR1KDM4EALDH1A1ESR2 | |
| SCHEMBL2332816 | 0.69 | ALDH1A1 (0.54) | ESR1KDM4EALDH1A1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | claimed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | claimed |
| EP-2533638-B1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2016-02-10 | — | — | EP | claimed |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-8759548-B2 | S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | claimed |
| CN-102869255-A | Novel S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-01-09 | — | — | CN | claimed |
| EP-2533638-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | claimed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | claimed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | disclosed |
| EP-2533638-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | ESR1 1525/4885KDM4E 2028/4885ALDH1A1 344/4885 |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | ESR1 1525/4885KDM4E 2028/4885ALDH1A1 344/4885 |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | ESR1 1525/4885KDM4E 2028/4885ALDH1A1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.